Homepage
Author:
Immunic, Inc.
Posted Date:
April 9, 2026
Immunic to Participate in Scientific and Medical Conferences in April
Immunic, Inc.
April 9, 2026
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
Immunic, Inc.
April 1, 2026
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Immunic, Inc.
March 31, 2026
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
Immunic, Inc.
March 10, 2026
Immunic to Participate in Investor Conferences in March
Immunic, Inc.
March 3, 2026
Immunic Announces Closing of Oversubscribed Private Placement Financing
Immunic, Inc.
February 17, 2026
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Immunic, Inc.
February 13, 2026
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic, Inc.
February 4, 2026
